Navinci Enters High-Stakes Spatial Biology Arena with Omni Kit

UPPSALA, Sweden – April 29, 2026 – In a move set to intensify the race for biological discovery, Swedish life science company Navinci today launched Omni, a line of fully customized kits designed to illuminate the complex world of protein interactions directly within tissue. The new technology promises to provide researchers with an unprecedented view of cellular machinery, potentially accelerating breakthroughs in medicine and drug development.

The launch positions Navinci, a company with deep roots in molecular detection technology, as a formidable new contender in the burgeoning spatial omics market—a sector projected to grow at a compound annual growth rate (CAGR) of over 16% to surpass $3.3 billion by 2034. By focusing on a specific, challenging niche—spatial interactomics—the company is betting that a deeper, more functional view of biology is what researchers need next.

A Technological Leap in Seeing Cellular Conversations

At the heart of the Omni launch is Navinci's proprietary in situ proximity ligation assay (isPLA) technology. While many existing spatial biology tools excel at identifying which proteins are present in a tissue sample and in what quantity, Omni is engineered to answer a more intricate question: how are these proteins interacting with each other in their native environment?

This is a critical distinction. Proteins rarely act alone; they form complex networks and signaling pathways to carry out their functions. The Omni kit enables the simultaneous detection of up to nine different protein-protein interactions, or target pairs, within a single tissue section. It works by using pairs of antibodies, each tagged with a unique DNA oligonucleotide. When two target proteins are in close proximity—indicating an interaction—the DNA tags are close enough to be joined and amplified. This creates a detectable signal precisely at the location of the interaction, effectively drawing a map of the cell's social network.

The technology’s power was demonstrated in a proof-of-concept study conducted with Uppsala University, the results of which are available on the pre-print server BioRxiv. The study confirmed Omni's high sensitivity and specificity in diverse sample types, including clinically vital formalin-fixed paraffin-embedded (FFPE) tissues, which are notoriously difficult to work with but represent a vast archive of patient samples.

"By revealing protein-protein interactions, post-translational modifications, and single protein targets simultaneously in situ, Omni enables scientists to capture complex biological interactions in their native context," the company stated in its official release.

Navigating a Crowded and Competitive Market

Navinci is entering a field populated by established players and well-funded competitors like NanoString, Akoya Biosciences, and Lunaphore. These companies have pioneered the spatial biology landscape, offering platforms capable of detecting hundreds, or even over a thousand, proteins on a single slide. The field has gained such prominence that spatial proteomics was named Nature Methods' "Method of the Year 2024," highlighting its transformative potential.

However, Navinci's strategy appears to be one of targeted differentiation rather than direct competition on the sheer number of proteins measured. By focusing on interactomics, it addresses a key challenge that remains a bottleneck for many researchers. Furthermore, the company is tackling a major barrier to adoption: workflow complexity. A common frustration in spatial proteomics is the time-consuming process of optimizing antibodies for multiplexed experiments. Navinci aims to solve this by providing pre-conjugated, validated antibodies, allowing researchers to get to their results faster.

This focus on usability is further reflected in its dual business model. Omni is available as a ready-to-use kit for labs that want to run experiments in-house, but also as a full-service offering where Navinci's own experts perform the entire experiment. This hybrid approach widens the technology's accessibility, catering to both experienced labs and those without the specialized equipment or expertise, thereby lowering the barrier to entry.

Accelerating the Path from Bench to Bedside

The ultimate promise of spatial interactomics lies in its potential to revolutionize medicine. By providing a more nuanced understanding of disease mechanisms, technologies like Omni could dramatically accelerate drug discovery and the development of precision medicine. For example, in immuno-oncology, understanding how immune cells interact with tumor cells within the tumor microenvironment is key to developing more effective immunotherapies.

Navinci offers pre-validated panels for key research areas, including MAPK signaling, immuno-oncology, and TCR/BCR immune profiling, signaling a clear focus on these high-impact fields. The ability to visualize these intricate signaling pathways directly in patient tissue could lead to the discovery of new biomarkers for diagnosing disease, predicting patient response to therapy, or identifying novel drug targets.

While the potential is immense, the field still faces challenges related to the high cost of instrumentation, data analysis complexity, and a lack of standardization across platforms. The vast datasets generated by spatial technologies require sophisticated bioinformatics tools and expertise to interpret, which can be a hurdle for many research groups.

With a recent infusion of €5.3 million in funding in June 2025 and a reported 72% sales growth in the same year, Navinci is building significant momentum. By combining its unique technological focus on protein interactions with a pragmatic approach to usability and market access, the company is making a strong case that the next great leap in biology will come not just from counting the components of a cell, but from watching how they work together.